Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects

In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high e...

Full description

Saved in:
Bibliographic Details
Published in:Journal of nanobiotechnology 2022-06, Vol.20 (1), p.276-20, Article 276
Main Authors: Kiaie, Seyed Hossein, Majidi Zolbanin, Naime, Ahmadi, Armin, Bagherifar, Rafieh, Valizadeh, Hadi, Kashanchi, Fatah, Jafari, Reza
Format: Article
Language:English
Subjects:
Analysis
Antigens
Cancer
Cholesterol
Clinical trials
Coronaviruses
COVID-19
Cytotoxicity
Dendritic cell
Dendritic cells
Disease
Efficiency
Gene expression
Genetic engineering
Genomes
Health aspects
Immune response
Immune system
Immunogenicity
Immunology
Immunotherapy
Infectious diseases
Lipid nanoparticles
Lipids
Lymphocytes
Macrophages
Messenger RNA
mRNA
mRNA delivery
Nanoparticles
Pandemics
Pharmacokinetics
Pharmacologic response
Pharmacology
Polyethylene glycol
Proteins
Public health
Review
Synthesis
Toll-like receptors
Vaccines
Vectors (Biology)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c597t-c3129ebfae2b81c7989c9e53c0e60ff63016f5fd4e69b770c5b34af0696fe9f83
cites cdi_FETCH-LOGICAL-c597t-c3129ebfae2b81c7989c9e53c0e60ff63016f5fd4e69b770c5b34af0696fe9f83
container_end_page 20
container_issue 1
container_start_page 276
container_title Journal of nanobiotechnology
container_volume 20
creator Kiaie, Seyed Hossein
Majidi Zolbanin, Naime
Ahmadi, Armin
Bagherifar, Rafieh
Valizadeh, Hadi
Kashanchi, Fatah
Jafari, Reza
description In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high efficiency, safety and adverse effects challenges due to the uncontrolled immune responses and inappropriate pharmacological interventions could limit this tremendous efficacy. The current study reveals the interplay of immune responses with LNP compositions and characterization and clarifies the interaction of mRNA-LNP therapeutics with dendritic, macrophages, neutrophile cells, and complement. Then, pharmacological profiles for mRNA-LNP delivery, including pharmacokinetics and cellular trafficking, were discussed in detail in cancer types and infectious diseases. This review study opens a new and vital landscape to improve multidisciplinary therapeutics on mRNA-LNP through modulation of immunopharmacological responses in clinical trials.
doi_str_mv 10.1186/s12951-022-01478-7
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_817e4fb03f024a9683a6fc367f4d3e2e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A707178700</galeid><doaj_id>oai_doaj_org_article_817e4fb03f024a9683a6fc367f4d3e2e</doaj_id><sourcerecordid>A707178700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-c3129ebfae2b81c7989c9e53c0e60ff63016f5fd4e69b770c5b34af0696fe9f83</originalsourceid><addsrcrecordid>eNptUk1v1DAUjBCIlsIf4IAiceKQ4o_EHxyQVhWFlVYFbeFsOc5z1qskDnZSwb-vt1vaRkI--Gk8M37vabLsLUbnGAv2MWIiK1wgQgqESy4K_iw7TQUvKK6q50_qk-xVjHuUmCUpX2YntOIIiwqfZtdbMDBMuW5u9GAg5m7I--3Vqthc_cinHQQ9wjw5Ez_lru_nwXe-dUZ3uR6afNzp0GvziMURzBRfZy-s7iK8ub_Psl-XX35efCs237-uL1abwlSST4WhqX-orQZSC2y4FNJIqKhBwJC1jCLMbGWbEpisOUemqmmpLWKSWZBW0LNsffRtvN6rMbheh7_Ka6fuAB9apUPqvQMlMIfS1ohaREotmaCaWUMZt2VDgUDy-nz0Gue6h-awk6C7henyZXA71fobJbFMq2fJ4P29QfC_Z4iT2vs5DGl-RRgXJP1bokdWq1NXbrA-mZneRaNWHHHMBUcH1vl_WOk00DvjB7Au4QvBh4UgcSb4M7V6jlGtr7dLLjlyTfAxBrAPQ2KkDrlSx1yplBZ1lyvFk-jd0_U8SP4Fid4CIzzHHA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2678202440</pqid></control><display><type>article</type><title>Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Kiaie, Seyed Hossein ; Majidi Zolbanin, Naime ; Ahmadi, Armin ; Bagherifar, Rafieh ; Valizadeh, Hadi ; Kashanchi, Fatah ; Jafari, Reza</creator><creatorcontrib>Kiaie, Seyed Hossein ; Majidi Zolbanin, Naime ; Ahmadi, Armin ; Bagherifar, Rafieh ; Valizadeh, Hadi ; Kashanchi, Fatah ; Jafari, Reza</creatorcontrib><description>In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high efficiency, safety and adverse effects challenges due to the uncontrolled immune responses and inappropriate pharmacological interventions could limit this tremendous efficacy. The current study reveals the interplay of immune responses with LNP compositions and characterization and clarifies the interaction of mRNA-LNP therapeutics with dendritic, macrophages, neutrophile cells, and complement. Then, pharmacological profiles for mRNA-LNP delivery, including pharmacokinetics and cellular trafficking, were discussed in detail in cancer types and infectious diseases. This review study opens a new and vital landscape to improve multidisciplinary therapeutics on mRNA-LNP through modulation of immunopharmacological responses in clinical trials.</description><identifier>ISSN: 1477-3155</identifier><identifier>EISSN: 1477-3155</identifier><identifier>DOI: 10.1186/s12951-022-01478-7</identifier><identifier>PMID: 35701851</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antigens ; Cancer ; Cholesterol ; Clinical trials ; Coronaviruses ; COVID-19 ; Cytotoxicity ; Dendritic cell ; Dendritic cells ; Disease ; Efficiency ; Gene expression ; Genetic engineering ; Genomes ; Health aspects ; Immune response ; Immune system ; Immunogenicity ; Immunology ; Immunotherapy ; Infectious diseases ; Lipid nanoparticles ; Lipids ; Lymphocytes ; Macrophages ; Messenger RNA ; mRNA ; mRNA delivery ; Nanoparticles ; Pandemics ; Pharmacokinetics ; Pharmacologic response ; Pharmacology ; Polyethylene glycol ; Proteins ; Public health ; Review ; Synthesis ; Toll-like receptors ; Vaccines ; Vectors (Biology)</subject><ispartof>Journal of nanobiotechnology, 2022-06, Vol.20 (1), p.276-20, Article 276</ispartof><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2022 BioMed Central Ltd.</rights><rights>2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-c3129ebfae2b81c7989c9e53c0e60ff63016f5fd4e69b770c5b34af0696fe9f83</citedby><cites>FETCH-LOGICAL-c597t-c3129ebfae2b81c7989c9e53c0e60ff63016f5fd4e69b770c5b34af0696fe9f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194786/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2678202440?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,38516,43895,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35701851$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kiaie, Seyed Hossein</creatorcontrib><creatorcontrib>Majidi Zolbanin, Naime</creatorcontrib><creatorcontrib>Ahmadi, Armin</creatorcontrib><creatorcontrib>Bagherifar, Rafieh</creatorcontrib><creatorcontrib>Valizadeh, Hadi</creatorcontrib><creatorcontrib>Kashanchi, Fatah</creatorcontrib><creatorcontrib>Jafari, Reza</creatorcontrib><title>Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects</title><title>Journal of nanobiotechnology</title><addtitle>J Nanobiotechnology</addtitle><description>In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high efficiency, safety and adverse effects challenges due to the uncontrolled immune responses and inappropriate pharmacological interventions could limit this tremendous efficacy. The current study reveals the interplay of immune responses with LNP compositions and characterization and clarifies the interaction of mRNA-LNP therapeutics with dendritic, macrophages, neutrophile cells, and complement. Then, pharmacological profiles for mRNA-LNP delivery, including pharmacokinetics and cellular trafficking, were discussed in detail in cancer types and infectious diseases. This review study opens a new and vital landscape to improve multidisciplinary therapeutics on mRNA-LNP through modulation of immunopharmacological responses in clinical trials.</description><subject>Analysis</subject><subject>Antigens</subject><subject>Cancer</subject><subject>Cholesterol</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytotoxicity</subject><subject>Dendritic cell</subject><subject>Dendritic cells</subject><subject>Disease</subject><subject>Efficiency</subject><subject>Gene expression</subject><subject>Genetic engineering</subject><subject>Genomes</subject><subject>Health aspects</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunogenicity</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Infectious diseases</subject><subject>Lipid nanoparticles</subject><subject>Lipids</subject><subject>Lymphocytes</subject><subject>Macrophages</subject><subject>Messenger RNA</subject><subject>mRNA</subject><subject>mRNA delivery</subject><subject>Nanoparticles</subject><subject>Pandemics</subject><subject>Pharmacokinetics</subject><subject>Pharmacologic response</subject><subject>Pharmacology</subject><subject>Polyethylene glycol</subject><subject>Proteins</subject><subject>Public health</subject><subject>Review</subject><subject>Synthesis</subject><subject>Toll-like receptors</subject><subject>Vaccines</subject><subject>Vectors (Biology)</subject><issn>1477-3155</issn><issn>1477-3155</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1v1DAUjBCIlsIf4IAiceKQ4o_EHxyQVhWFlVYFbeFsOc5z1qskDnZSwb-vt1vaRkI--Gk8M37vabLsLUbnGAv2MWIiK1wgQgqESy4K_iw7TQUvKK6q50_qk-xVjHuUmCUpX2YntOIIiwqfZtdbMDBMuW5u9GAg5m7I--3Vqthc_cinHQQ9wjw5Ez_lru_nwXe-dUZ3uR6afNzp0GvziMURzBRfZy-s7iK8ub_Psl-XX35efCs237-uL1abwlSST4WhqX-orQZSC2y4FNJIqKhBwJC1jCLMbGWbEpisOUemqmmpLWKSWZBW0LNsffRtvN6rMbheh7_Ka6fuAB9apUPqvQMlMIfS1ohaREotmaCaWUMZt2VDgUDy-nz0Gue6h-awk6C7henyZXA71fobJbFMq2fJ4P29QfC_Z4iT2vs5DGl-RRgXJP1bokdWq1NXbrA-mZneRaNWHHHMBUcH1vl_WOk00DvjB7Au4QvBh4UgcSb4M7V6jlGtr7dLLjlyTfAxBrAPQ2KkDrlSx1yplBZ1lyvFk-jd0_U8SP4Fid4CIzzHHA</recordid><startdate>20220614</startdate><enddate>20220614</enddate><creator>Kiaie, Seyed Hossein</creator><creator>Majidi Zolbanin, Naime</creator><creator>Ahmadi, Armin</creator><creator>Bagherifar, Rafieh</creator><creator>Valizadeh, Hadi</creator><creator>Kashanchi, Fatah</creator><creator>Jafari, Reza</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QO</scope><scope>7TB</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220614</creationdate><title>Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects</title><author>Kiaie, Seyed Hossein ; Majidi Zolbanin, Naime ; Ahmadi, Armin ; Bagherifar, Rafieh ; Valizadeh, Hadi ; Kashanchi, Fatah ; Jafari, Reza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-c3129ebfae2b81c7989c9e53c0e60ff63016f5fd4e69b770c5b34af0696fe9f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Antigens</topic><topic>Cancer</topic><topic>Cholesterol</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytotoxicity</topic><topic>Dendritic cell</topic><topic>Dendritic cells</topic><topic>Disease</topic><topic>Efficiency</topic><topic>Gene expression</topic><topic>Genetic engineering</topic><topic>Genomes</topic><topic>Health aspects</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunogenicity</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Infectious diseases</topic><topic>Lipid nanoparticles</topic><topic>Lipids</topic><topic>Lymphocytes</topic><topic>Macrophages</topic><topic>Messenger RNA</topic><topic>mRNA</topic><topic>mRNA delivery</topic><topic>Nanoparticles</topic><topic>Pandemics</topic><topic>Pharmacokinetics</topic><topic>Pharmacologic response</topic><topic>Pharmacology</topic><topic>Polyethylene glycol</topic><topic>Proteins</topic><topic>Public health</topic><topic>Review</topic><topic>Synthesis</topic><topic>Toll-like receptors</topic><topic>Vaccines</topic><topic>Vectors (Biology)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kiaie, Seyed Hossein</creatorcontrib><creatorcontrib>Majidi Zolbanin, Naime</creatorcontrib><creatorcontrib>Ahmadi, Armin</creatorcontrib><creatorcontrib>Bagherifar, Rafieh</creatorcontrib><creatorcontrib>Valizadeh, Hadi</creatorcontrib><creatorcontrib>Kashanchi, Fatah</creatorcontrib><creatorcontrib>Jafari, Reza</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Science in Context</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Mechanical &amp; Transportation Engineering Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of nanobiotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kiaie, Seyed Hossein</au><au>Majidi Zolbanin, Naime</au><au>Ahmadi, Armin</au><au>Bagherifar, Rafieh</au><au>Valizadeh, Hadi</au><au>Kashanchi, Fatah</au><au>Jafari, Reza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects</atitle><jtitle>Journal of nanobiotechnology</jtitle><addtitle>J Nanobiotechnology</addtitle><date>2022-06-14</date><risdate>2022</risdate><volume>20</volume><issue>1</issue><spage>276</spage><epage>20</epage><pages>276-20</pages><artnum>276</artnum><issn>1477-3155</issn><eissn>1477-3155</eissn><abstract>In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high efficiency, safety and adverse effects challenges due to the uncontrolled immune responses and inappropriate pharmacological interventions could limit this tremendous efficacy. The current study reveals the interplay of immune responses with LNP compositions and characterization and clarifies the interaction of mRNA-LNP therapeutics with dendritic, macrophages, neutrophile cells, and complement. Then, pharmacological profiles for mRNA-LNP delivery, including pharmacokinetics and cellular trafficking, were discussed in detail in cancer types and infectious diseases. This review study opens a new and vital landscape to improve multidisciplinary therapeutics on mRNA-LNP through modulation of immunopharmacological responses in clinical trials.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>35701851</pmid><doi>10.1186/s12951-022-01478-7</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1477-3155
ispartof Journal of nanobiotechnology, 2022-06, Vol.20 (1), p.276-20, Article 276
issn 1477-3155
1477-3155
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_817e4fb03f024a9683a6fc367f4d3e2e
source Publicly Available Content (ProQuest); PubMed Central; Coronavirus Research Database
subjects Analysis
Antigens
Cancer
Cholesterol
Clinical trials
Coronaviruses
COVID-19
Cytotoxicity
Dendritic cell
Dendritic cells
Disease
Efficiency
Gene expression
Genetic engineering
Genomes
Health aspects
Immune response
Immune system
Immunogenicity
Immunology
Immunotherapy
Infectious diseases
Lipid nanoparticles
Lipids
Lymphocytes
Macrophages
Messenger RNA
mRNA
mRNA delivery
Nanoparticles
Pandemics
Pharmacokinetics
Pharmacologic response
Pharmacology
Polyethylene glycol
Proteins
Public health
Review
Synthesis
Toll-like receptors
Vaccines
Vectors (Biology)
title Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A10%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20advances%20in%20mRNA-LNP%20therapeutics:%20immunological%20and%20pharmacological%20aspects&rft.jtitle=Journal%20of%20nanobiotechnology&rft.au=Kiaie,%20Seyed%20Hossein&rft.date=2022-06-14&rft.volume=20&rft.issue=1&rft.spage=276&rft.epage=20&rft.pages=276-20&rft.artnum=276&rft.issn=1477-3155&rft.eissn=1477-3155&rft_id=info:doi/10.1186/s12951-022-01478-7&rft_dat=%3Cgale_doaj_%3EA707178700%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c597t-c3129ebfae2b81c7989c9e53c0e60ff63016f5fd4e69b770c5b34af0696fe9f83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2678202440&rft_id=info:pmid/35701851&rft_galeid=A707178700&rfr_iscdi=true